SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 209 filers reported holding SAGE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,821,474 | -58.7% | 88,507 | -5.6% | 0.00% | -50.0% |
Q2 2023 | $4,406,667 | +10.5% | 93,719 | -1.4% | 0.00% | 0.0% |
Q1 2023 | $3,988,088 | +10.2% | 95,045 | +0.2% | 0.00% | 0.0% |
Q4 2022 | $3,618,913 | +1.1% | 94,885 | +3.8% | 0.00% | 0.0% |
Q3 2022 | $3,580,000 | +25.3% | 91,395 | +3.3% | 0.00% | +33.3% |
Q2 2022 | $2,857,000 | -12.6% | 88,446 | -10.4% | 0.00% | +50.0% |
Q1 2022 | $3,269,000 | -15.0% | 98,766 | +9.3% | 0.00% | 0.0% |
Q4 2021 | $3,845,000 | +0.5% | 90,372 | +4.7% | 0.00% | 0.0% |
Q3 2021 | $3,824,000 | -16.1% | 86,298 | +7.5% | 0.00% | 0.0% |
Q2 2021 | $4,559,000 | -12.7% | 80,265 | +15.1% | 0.00% | -33.3% |
Q1 2021 | $5,221,000 | +83.3% | 69,749 | +111.9% | 0.00% | +50.0% |
Q4 2020 | $2,848,000 | +173.6% | 32,916 | +93.3% | 0.00% | +100.0% |
Q3 2020 | $1,041,000 | +1477.3% | 17,030 | +971.1% | 0.00% | – |
Q2 2020 | $66,000 | +164.0% | 1,590 | +80.9% | 0.00% | – |
Q1 2020 | $25,000 | -28.6% | 879 | +79.4% | 0.00% | – |
Q4 2019 | $35,000 | -49.3% | 490 | 0.0% | 0.00% | – |
Q3 2019 | $69,000 | – | 490 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Integral Health Asset Management, LLC | 311,000 | $10,294,000 | 2.68% |
Palo Alto Investors LP | 851,719 | $28,192,000 | 2.18% |
Boxer Capital, LLC | 1,094,000 | $36,211,000 | 1.86% |
DAFNA Capital Management LLC | 180,306 | $5,968,000 | 1.56% |
Deep Track Capital, LP | 675,000 | $22,343,000 | 1.43% |
Bellevue Group AG | 3,052,404 | $101,034,000 | 1.17% |
Ikarian Capital, LLC | 249,907 | $8,272,000 | 1.09% |
Ikarian Capital, LLC | 250,000 | $8,275,000 | 1.09% |
Artal Group S.A. | 750,000 | $24,825,000 | 1.04% |
SECTOR GAMMA AS | 118,476 | $3,922,000 | 0.85% |